A regulatory filing indicates that Cambridge, MA-based Merrimack Pharmaceuticals has raised $35 million of an $80 Series F financing round, according to PE Week Wire. No investors were named in the filing, but Merrimack’s $65 million Series E round, closed in April of 2006, included Jennison Associates, Modal Capital, Sorenson Development, WT Investment Advisors Fund, and funds advised by Noonday Asset Management, TPG-Axon Capital, and others.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
